These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 3015011)

  • 21. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
    Nord CE
    J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
    [No Abstract]   [Full Text] [Related]  

  • 22. Synergistic activity of mecillinam in combination with the beta-lactamase inhibitors clavulanic acid and sulbactam.
    Neu HC
    Antimicrob Agents Chemother; 1982 Sep; 22(3):518-9. PubMed ID: 6291454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
    Fass RJ; Prior RB
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolution of beta-lactamase inhibitors.
    Rolinson GN
    Rev Infect Dis; 1991; 13 Suppl 9():S727-32. PubMed ID: 1656513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
    Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
    Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergy of clavulanic acid, sulbactam and tazobactam (YTR 830) with amoxycillin against fifty beta-lactamase-producing strains of Haemophilus influenzae.
    Simonet M; Moittie D; Philippon A; Descamps P; Veron M
    J Antimicrob Chemother; 1989 May; 23(5):798-800. PubMed ID: 2547748
    [No Abstract]   [Full Text] [Related]  

  • 28. In vitro activity of cefodizime (HR-221) in combination with beta-lactamase inhibitors.
    Segatore B; Perilli M; Franceschini N; Setacci D; Oratore A; Amicosante G
    J Chemother; 1993 Jun; 5(3):147-50. PubMed ID: 8396624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria.
    Chang SC; Hsu LY; Luh KT; Hsieh WC
    J Formos Med Assoc; 1991 Oct; 90(10):947-52. PubMed ID: 1685175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors.
    Tajada P; Gomez-Graces JL; Alós JI; Balas D; Cogollos R
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1924-5. PubMed ID: 8843305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.
    Knapp CC; Sierra-Madero J; Washington JA
    Diagn Microbiol Infect Dis; 1989; 12(6):511-5. PubMed ID: 2560423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibilities of beta-lactamase-positive and -negative strains of Campylobacter coli to beta-lactam agents.
    Lachance N; Gaudreau C; Lamothe F; Turgeon F
    Antimicrob Agents Chemother; 1993 May; 37(5):1174-6. PubMed ID: 8390812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads.
    Jacobs MR; Aronoff SC; Johenning S; Yamabe S
    J Antimicrob Chemother; 1986 Aug; 18(2):177-84. PubMed ID: 3019984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro evaluation of SF-2103A, a novel carbapenem antibiotic, as a beta-lactamase inhibitor.
    Niwa T; Yoshida T; Tamura A; Kazuno Y; Inouye S; Ito T; Kojima M
    J Antibiot (Tokyo); 1986 Jul; 39(7):943-55. PubMed ID: 3019978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro effect of YTR (tazobactam) on plasmid and chromosomally mediated beta-lactamases.
    Stobberingh EE
    Chemotherapy; 1990; 36(3):209-14. PubMed ID: 2159864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents.
    Vanjak D; Muller-Serieys C; Picard B; Bergogne-Berezin E; Lambert-Zechovsky N
    Eur J Clin Microbiol Infect Dis; 1995 Nov; 14(11):972-8. PubMed ID: 8654448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined antibacterial activity of amoxicillin with clavulanic acid against ampicillin-resistant strains.
    Matsuura M; Nakazawa H; Hashimoto T; Mitsuhashi S
    Antimicrob Agents Chemother; 1980 Jun; 17(6):908-11. PubMed ID: 6967713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic activity of piperacillin in combination with beta-lactamase inhibitors.
    Neu HC; Fu KP
    Antimicrob Agents Chemother; 1980 Oct; 18(4):582-5. PubMed ID: 6255862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.